GT Biopharma is trading 6.35% down at $5.60 after a sharp post-split rally.
- The 1-for-25 reverse stock split became effective September 8, 2026, reducing outstanding shares from approximately 45.1 million to 1.8 million and enabling split-adjusted trading on Nasdaq.
- Shares surged 2,074.07% on September 8 and 14.13% on September 9; the decline appears tied to speculative post-split activity and profit-taking.
- Broader markets are also lower following hotter producer-inflation data.